PDCD1 and cutaneous melanoma: One line of such evidence described in 2015, follows the use of anti-programmed cell death-1 (PD-1) therapies such as pembrolizumab in a patient with BRAF wild-type cutaneous melanoma that subsequently developed autoimmune diabetes [391].